Research status explorer
See where each compound sits in published research and clinical development. This describes the molecule’s research history — not the regulatory status of any Vital Edge Science product, and not a recommendation, efficacy claim or dosing guidance.
| Compound | Research line | Research status | Development note | |
|---|---|---|---|---|
| 5-Amino-1MQ | Ignite | Preclinical | Cellular and animal research | View → |
| BPC-157 | Rebuild | Preclinical | Predominantly preclinical research | View → |
| CJC-1295 | Peak | Human Research | Early/historical clinical research | View → |
| Cagrilintide | Ignite | Phase 3 | Active clinical development | View → |
| DSIP | Neuro | Human Research | Historical human research | View → |
| Epithalon | Rebuild | Human Research | Limited/historical human research | View → |
| GHK-Cu | Rebuild | Human Research | Translational/human research | View → |
| GHRP-2 | Peak | Human Research | Experimental endocrine research | View → |
| Glutathione | Rebuild | Human Research | Extensive human literature | View → |
| HCG | Ignite | Approved Molecule* | Established medicine | View → |
| Ipamorelin | Peak | Human Research | Human pharmacology/clinical research | View → |
| KPV | Rebuild | Preclinical | Cellular and animal research | View → |
| Kisspeptin-10 | Enhance | Human Research | Active experimental human research | View → |
| MOTS-c | Ignite | Phase 2a | Early clinical investigation | View → |
| Melanotan I | Enhance | Approved Molecule* | Established pharmaceutical ingredient | View → |
| Melanotan II | Enhance | Human Research | Early/historical human research | View → |
| NAD+ | Ignite | Human Research | Broad translational research | View → |
| PT-141 | Enhance | Approved Molecule* | Established pharmaceutical ingredient | View → |
| Retatrutide | Ignite | Phase 3 | Active clinical development | View → |
| SS-31 | Rebuild | Approved Molecule* | Accelerated approval / confirmatory research ongoing | View → |
| Selank | Neuro | Human Research | Limited/regional clinical research | View → |
| Semaglutide | Ignite | Approved Molecule* | Extensive clinical development | View → |
| Semax | Neuro | Human Research | Limited/regional clinical research | View → |
| Sermorelin | Peak | Human Research | Extensive historical human research | View → |
| Tesamorelin | Peak | Approved Molecule* | Established pharmaceutical ingredient | View → |
| Thymosin Alpha-1 | Rebuild | Phase 3 | Indication-specific clinical development | View → |
| Thymosin Beta-4 (TB-4) | Rebuild | Phase 2 | Human clinical research | View → |
| Tirzepatide | Ignite | Approved Molecule* | Ongoing clinical research | View → |
Limited/historical human research
View research →Active experimental human research
View research →Established pharmaceutical ingredient
View research →Early/historical human research
View research →Established pharmaceutical ingredient
View research →Accelerated approval / confirmatory research ongoing
View research →Established pharmaceutical ingredient
View research →Indication-specific clinical development
View research →*Approval refers to specific pharmaceutical products, formulations, jurisdictions and indications containing this molecule. It does not indicate that the Vital Edge Science research product is approved.
